Pain is a largely neglected symptom in patients with amyotrophic lateral sclerosis (ALS) although it is reported by most of these patients. It occurs at all stages of the disease and can be an onset symptom preceding motor dysfunction. Pain is correlated with a deterioration in patients’ quality of life and increased prevalence of depression. In the later stages of ALS, pain can be severe enough to require increased use of sedative and analgesic drugs, and is among the events that predict clinical deterioration and death. The site of pain depends on the pain type or underlying mechanism (eg, painful cramps, nociceptive pain, or neuropathic pain). Given the multifactorial nature of pain in patients with ALS, diff erent treatments have been suggested, ranging from non-steroidal anti-infl ammatory drugs, drugs for neuropathic pain, opioids, and cannabinoids, to physical therapy strategies and preventive assistive devices. Further understanding of the pathophysiology is crucial to drive assessment in clinical trials of therapeutic strategies targeted at specifi c mechanisms and studies of individualised therapies.

Pain in amyotrophic lateral sclerosis

CHIO', Adriano
First
;
LAURIA, GIUSEPPE
2017-01-01

Abstract

Pain is a largely neglected symptom in patients with amyotrophic lateral sclerosis (ALS) although it is reported by most of these patients. It occurs at all stages of the disease and can be an onset symptom preceding motor dysfunction. Pain is correlated with a deterioration in patients’ quality of life and increased prevalence of depression. In the later stages of ALS, pain can be severe enough to require increased use of sedative and analgesic drugs, and is among the events that predict clinical deterioration and death. The site of pain depends on the pain type or underlying mechanism (eg, painful cramps, nociceptive pain, or neuropathic pain). Given the multifactorial nature of pain in patients with ALS, diff erent treatments have been suggested, ranging from non-steroidal anti-infl ammatory drugs, drugs for neuropathic pain, opioids, and cannabinoids, to physical therapy strategies and preventive assistive devices. Further understanding of the pathophysiology is crucial to drive assessment in clinical trials of therapeutic strategies targeted at specifi c mechanisms and studies of individualised therapies.
2017
16
2
144
157
http://www.journals.elsevier.com/the-lancet-neurology/
Neurology (clinical)
Chiò, Adriano; Mora, Gabriele; Lauria, Giuseppe
File in questo prodotto:
File Dimensione Formato  
D-16-00600 Chio_R4_141116.docx

Accesso riservato

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 412.58 kB
Formato Adobe PDF
412.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
D-16-00600 Chio_R4_141116.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 357.43 kB
Formato Adobe PDF
357.43 kB Adobe PDF Visualizza/Apri
Lancet Neurology 2017.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 225.28 kB
Formato Adobe PDF
225.28 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1636247
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 84
  • ???jsp.display-item.citation.isi??? 82
social impact